Alpha Cognition (NASDAQ:ACOG) Upgraded at Raymond James

Raymond James upgraded shares of Alpha Cognition (NASDAQ:ACOG) to a moderate buy rating in a report published on Tuesday morning,Zacks.com reports.

Separately, HC Wainwright initiated coverage on Alpha Cognition in a research report on Tuesday, March 18th. They set a “buy” rating and a $20.00 price objective for the company.

Alpha Cognition Price Performance

Alpha Cognition stock opened at $5.31 on Tuesday. Alpha Cognition has a 52-week low of $4.66 and a 52-week high of $7.00. The firm has a market cap of $85.07 million, a price-to-earnings ratio of -2.07 and a beta of 2.50. The firm’s 50-day moving average price is $5.86.

Institutional Investors Weigh In On Alpha Cognition

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. National Bank of Canada FI acquired a new position in Alpha Cognition during the 4th quarter valued at about $69,000. Manatuck Hill Partners LLC bought a new position in shares of Alpha Cognition in the fourth quarter valued at approximately $395,000. Tudor Investment Corp ET AL acquired a new position in shares of Alpha Cognition during the fourth quarter valued at approximately $412,000. MYDA Advisors LLC bought a new stake in Alpha Cognition during the fourth quarter worth approximately $589,000. Finally, Bleichroeder LP acquired a new stake in Alpha Cognition in the fourth quarter worth approximately $1,024,000.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.